PL375734A1 - Preparat do podawania drogą żołądkowo-jelitową zawierający ekstrat z zielonej herbaty i donor NO - Google Patents

Preparat do podawania drogą żołądkowo-jelitową zawierający ekstrat z zielonej herbaty i donor NO

Info

Publication number
PL375734A1
PL375734A1 PL03375734A PL37573403A PL375734A1 PL 375734 A1 PL375734 A1 PL 375734A1 PL 03375734 A PL03375734 A PL 03375734A PL 37573403 A PL37573403 A PL 37573403A PL 375734 A1 PL375734 A1 PL 375734A1
Authority
PL
Poland
Prior art keywords
formulation
donor
green tea
tea extract
containing green
Prior art date
Application number
PL03375734A
Other languages
English (en)
Other versions
PL212978B1 (pl
Inventor
Heinz Schneider
Original Assignee
Fresenius Kabi Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi Deutschland Gmbh filed Critical Fresenius Kabi Deutschland Gmbh
Publication of PL375734A1 publication Critical patent/PL375734A1/pl
Publication of PL212978B1 publication Critical patent/PL212978B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL375734A 2002-12-09 2003-11-13 Zastosowanie kompozycji zawierajacej ekstrakt z zielonej herbaty i donor tlenku azotu do wytwarzania preparatu do podawania droga zoladkowo-jelitowa PL212978B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10257360A DE10257360A1 (de) 2002-12-09 2002-12-09 Gastro-intestinal verabreichbare Formulierung und deren Verwendung

Publications (2)

Publication Number Publication Date
PL375734A1 true PL375734A1 (pl) 2005-12-12
PL212978B1 PL212978B1 (pl) 2012-12-31

Family

ID=32477462

Family Applications (1)

Application Number Title Priority Date Filing Date
PL375734A PL212978B1 (pl) 2002-12-09 2003-11-13 Zastosowanie kompozycji zawierajacej ekstrakt z zielonej herbaty i donor tlenku azotu do wytwarzania preparatu do podawania droga zoladkowo-jelitowa

Country Status (24)

Country Link
US (1) US20060121125A1 (pl)
EP (1) EP1572175B1 (pl)
JP (1) JP2006510640A (pl)
KR (1) KR101031989B1 (pl)
CN (1) CN100367941C (pl)
AT (1) ATE345116T1 (pl)
AU (1) AU2003288047B2 (pl)
BR (1) BRPI0315075A8 (pl)
CA (1) CA2499006C (pl)
DE (2) DE10257360A1 (pl)
DK (1) DK1572175T3 (pl)
ES (1) ES2276136T3 (pl)
HK (1) HK1087913A1 (pl)
HR (1) HRP20050511B1 (pl)
IL (1) IL168854A (pl)
IS (1) IS2432B (pl)
MX (1) MXPA05006111A (pl)
NO (1) NO332734B1 (pl)
PL (1) PL212978B1 (pl)
PT (1) PT1572175E (pl)
RU (1) RU2314824C2 (pl)
TW (1) TWI349563B (pl)
WO (1) WO2004052352A1 (pl)
ZA (1) ZA200501924B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1036746C2 (nl) * 2009-03-20 2010-09-21 Glnp Holding B.V. Kit van onderdelen bevattende l-glutamine en egcg.
WO2014150996A1 (en) * 2013-03-15 2014-09-25 Cba Pharma, Inc. Cancer treatment
EP3091859A1 (en) * 2013-12-18 2016-11-16 Abbott Laboratories Methods for increasing skeletal muscle protein synthesis using green tea extract
CN112334205B (zh) * 2018-06-21 2022-09-06 Gs 加德士 天然物质提取用溶剂组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE502414C2 (sv) * 1990-05-28 1995-10-16 Ljungqvist Olle Medical Ab Användning av glukos för framställning av lösning för preoperativ administrering samt infusionslösning därför
GB9403935D0 (en) * 1994-03-01 1994-04-20 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
HUP9800049A3 (en) * 1995-02-23 1999-01-28 Novartis Nutrition Ag Amino acid compositions and use thereof in clinical nutrition, and use of the said amino acids for preparing pharmaceutical compns. for the diminution of tnf
US5656608B1 (en) * 1995-02-23 2000-09-26 Novartis Nutrition Ltd Amino acid compositions and methods of treatment using same
GB9510037D0 (en) 1995-05-18 1995-07-12 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
JPH09227374A (ja) * 1996-02-28 1997-09-02 Taiyo Kagaku Co Ltd ストレスタンパク質産生抑制組成物
US6013273A (en) * 1997-01-27 2000-01-11 Novartis Nutrition Ag Treatment of endotoxic shock
JPH10248538A (ja) * 1997-03-10 1998-09-22 Cheil Sugar Co Ltd α−波増進飲料用組成物及びこれを含有する飲料
EP0875155A1 (en) * 1997-05-01 1998-11-04 N.V. Nutricia Peri-operative drink
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
US5904924A (en) * 1997-11-04 1999-05-18 Oncologics, Inc. Green nutritional powder composition
CA2368187A1 (en) * 1999-03-19 2000-09-28 Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by hmg-coa reductase inhibitors
EP1136073A1 (en) * 2000-03-22 2001-09-26 N.V. Nutricia Compositions suitable for the treatment of damage caused by ischemia/reperfusion or oxidative stress
AU2001267836A1 (en) * 2000-07-05 2002-01-14 Kenji Ohnaka Preservation fluid for cells and tissues
EP1402896A1 (en) * 2000-07-14 2004-03-31 Healthecon Ag Green tea extract and use thereof in treating renal dysfunction
US6423349B1 (en) * 2000-08-24 2002-07-23 Baxter International, Inc. Therapeutic nutrient composition for pre and post elective surgery

Also Published As

Publication number Publication date
EP1572175A1 (de) 2005-09-14
TW200418501A (en) 2004-10-01
JP2006510640A (ja) 2006-03-30
DE10257360A1 (de) 2004-07-08
WO2004052352A1 (de) 2004-06-24
IS2432B (is) 2008-10-15
HRP20050511A2 (en) 2005-10-31
MXPA05006111A (es) 2005-08-16
PT1572175E (pt) 2007-01-31
AU2003288047B2 (en) 2008-03-13
ZA200501924B (en) 2005-11-30
KR101031989B1 (ko) 2011-05-02
IS7836A (is) 2005-05-03
PL212978B1 (pl) 2012-12-31
HRP20050511B1 (en) 2008-01-31
CA2499006C (en) 2011-04-19
IL168854A (en) 2011-09-27
CA2499006A1 (en) 2004-06-24
BRPI0315075A8 (pt) 2017-12-19
US20060121125A1 (en) 2006-06-08
CN100367941C (zh) 2008-02-13
ES2276136T3 (es) 2007-06-16
BR0315075A (pt) 2005-08-16
RU2314824C2 (ru) 2008-01-20
CN1703210A (zh) 2005-11-30
ATE345116T1 (de) 2006-12-15
NO20052978L (no) 2005-06-17
DK1572175T3 (da) 2007-03-19
KR20050084207A (ko) 2005-08-26
NO332734B1 (no) 2012-12-27
TWI349563B (en) 2011-10-01
DE50305714D1 (de) 2006-12-28
RU2005111766A (ru) 2005-09-10
EP1572175B1 (de) 2006-11-15
HK1087913A1 (en) 2006-10-27
AU2003288047A1 (en) 2004-06-30
NO20052978D0 (no) 2005-06-17

Similar Documents

Publication Publication Date Title
MXPA03008045A (es) Nuevas composiciones de medicamentos en base a agentes anticolinergicos e inhibidores de pde-iv.
AU2002257587A1 (en) Novel medicament compositions on the basis of anticholinergics and PDE IV inhibitors
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
WO2002076499A3 (en) Combination treatment of pancreatic cancer
WO2006012213A3 (en) Composition and method for delivery of phytochemicals
CA2469369A1 (en) Compositions containing both sedative and non-sedative antihistamines
WO2005123032A3 (en) Haircare compositions and methods
AU2002362819A1 (en) Concentrate comprising green tea, grape skin extract and grape seed extract, the production thereof and the use of the same
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
HRP20050511A2 (en) Formulation, which can be administered gastrointestinally, containing green tea extract and an no donor
MY137752A (en) Medicament for treating aseptic inflammations containing anemonin as effective component
WO2005034861A3 (en) A dried biotherapeutic composition, uses, and device and methods for administration thereof
WO2004071374A3 (en) Once a day orally administered pharmaceutical compositions
TW200503735A (en) Composition and method for viral inhibition
AU2002215982A1 (en) Topical treatment of mastalgia with arometese inhibitors such as androstendione
TNSN07203A1 (en) Pharmaceutical compositions for the treatment of cellulite
PT1485154E (pt) Dispositivo de inalação de pó
EP1707567A4 (en) NEW FUSED CYCLE COMPOUND
WO2004080414A3 (en) Composition and method for treating inflammations by reducing c-reactive protein
WO2002017952A3 (en) Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
WO2001054676A3 (de) Formulierungen bei dehydratationszuständen
WO2005063757A3 (en) Novel crystalline forms of temozolomide
WO2003043632A3 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
WO2003059650A3 (de) Hülle einer score-karte
SI1572175T1 (sl) Formulacija iz ekstrakta zelenega caja in NO-donorja, ki se jo lahko daje gastrointestinalno